Baader Bank Aktiengesellschaft Takes $373,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Baader Bank Aktiengesellschaft bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,000 shares of the company's stock, valued at approximately $373,000. Baader Bank Aktiengesellschaft owned 0.11% of Eton Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ETON. Parkman Healthcare Partners LLC raised its position in Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company's stock valued at $1,561,000 after purchasing an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the 3rd quarter valued at approximately $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the 3rd quarter valued at approximately $90,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock valued at $390,000 after buying an additional 30,167 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock valued at $1,637,000 after purchasing an additional 32,365 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ETON has been the topic of several recent analyst reports. HC Wainwright increased their target price on Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. B. Riley began coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They set a "buy" rating and a $21.00 price target on the stock. Finally, Craig Hallum lifted their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON traded down $1.01 during trading hours on Monday, hitting $16.67. 271,602 shares of the company's stock traded hands, compared to its average volume of 362,524. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $17.80. The business has a fifty day moving average price of $13.50 and a 200-day moving average price of $8.77. The firm has a market capitalization of $434.25 million, a P/E ratio of -76.12 and a beta of 1.40.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.